Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Introduction: Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional depth to this complexity. Areas covered: Lymphoma classification follows the World Health Organization (WHO) system, which reflects international consensus and is based on pathological, genetic, and clinical factors. The present review focuses on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic and dendritic cell neoplasms, summarizing changes reflected in the 2016 revision to the WHO classification. These changes are critical to hematologists and other clinicians who care for patients with these disorders. Expert commentary: Lymphoma classification is a continually evolving field that needs to be responsive to new clinical, pathological, and molecular understanding of lymphoid neoplasia. Among the entities covered in this review, the 2016 revisions in the WHO classification particularly impact T-cell lymphomas, including a new umbrella category of T-follicular helper cell-derived lymphomas and evolving recognition of indolent T-cell lymphomas and lymphoproliferative disorders.

Original languageEnglish (US)
Pages (from-to)239-249
Number of pages11
JournalExpert Review of Hematology
Volume10
Issue number3
DOIs
StatePublished - Mar 4 2017

Fingerprint

T-Cell Lymphoma
Hodgkin Disease
Dendritic Cells
Lymphoma
Neoplasms
Lymphoproliferative Disorders
Helper-Inducer T-Lymphocytes
Patient Care
Lymphocytes
Population

Keywords

  • anaplastic large cell lymphoma
  • angioimmunoblastic T-cell lymphoma
  • dendritic cell tumors
  • histiocytic sarcoma
  • Hodgkin lymphoma
  • lymphoma classification
  • Non-Hodgkin lymphoma
  • peripheral T-cell lymphoma
  • T-cell lymphoproliferative disorder
  • World Health Organization (WHO)

ASJC Scopus subject areas

  • Hematology

Cite this

Lymphoma classification update : T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. / Jiang, Manli; Bennani, Nabila; Feldman, Andrew L.

In: Expert Review of Hematology, Vol. 10, No. 3, 04.03.2017, p. 239-249.

Research output: Contribution to journalReview article

@article{473215f8c0f342d099607729effbe319,
title = "Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms",
abstract = "Introduction: Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional depth to this complexity. Areas covered: Lymphoma classification follows the World Health Organization (WHO) system, which reflects international consensus and is based on pathological, genetic, and clinical factors. The present review focuses on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic and dendritic cell neoplasms, summarizing changes reflected in the 2016 revision to the WHO classification. These changes are critical to hematologists and other clinicians who care for patients with these disorders. Expert commentary: Lymphoma classification is a continually evolving field that needs to be responsive to new clinical, pathological, and molecular understanding of lymphoid neoplasia. Among the entities covered in this review, the 2016 revisions in the WHO classification particularly impact T-cell lymphomas, including a new umbrella category of T-follicular helper cell-derived lymphomas and evolving recognition of indolent T-cell lymphomas and lymphoproliferative disorders.",
keywords = "anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, dendritic cell tumors, histiocytic sarcoma, Hodgkin lymphoma, lymphoma classification, Non-Hodgkin lymphoma, peripheral T-cell lymphoma, T-cell lymphoproliferative disorder, World Health Organization (WHO)",
author = "Manli Jiang and Nabila Bennani and Feldman, {Andrew L}",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/17474086.2017.1281122",
language = "English (US)",
volume = "10",
pages = "239--249",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Lymphoma classification update

T2 - T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms

AU - Jiang, Manli

AU - Bennani, Nabila

AU - Feldman, Andrew L

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Introduction: Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional depth to this complexity. Areas covered: Lymphoma classification follows the World Health Organization (WHO) system, which reflects international consensus and is based on pathological, genetic, and clinical factors. The present review focuses on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic and dendritic cell neoplasms, summarizing changes reflected in the 2016 revision to the WHO classification. These changes are critical to hematologists and other clinicians who care for patients with these disorders. Expert commentary: Lymphoma classification is a continually evolving field that needs to be responsive to new clinical, pathological, and molecular understanding of lymphoid neoplasia. Among the entities covered in this review, the 2016 revisions in the WHO classification particularly impact T-cell lymphomas, including a new umbrella category of T-follicular helper cell-derived lymphomas and evolving recognition of indolent T-cell lymphomas and lymphoproliferative disorders.

AB - Introduction: Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional depth to this complexity. Areas covered: Lymphoma classification follows the World Health Organization (WHO) system, which reflects international consensus and is based on pathological, genetic, and clinical factors. The present review focuses on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic and dendritic cell neoplasms, summarizing changes reflected in the 2016 revision to the WHO classification. These changes are critical to hematologists and other clinicians who care for patients with these disorders. Expert commentary: Lymphoma classification is a continually evolving field that needs to be responsive to new clinical, pathological, and molecular understanding of lymphoid neoplasia. Among the entities covered in this review, the 2016 revisions in the WHO classification particularly impact T-cell lymphomas, including a new umbrella category of T-follicular helper cell-derived lymphomas and evolving recognition of indolent T-cell lymphomas and lymphoproliferative disorders.

KW - anaplastic large cell lymphoma

KW - angioimmunoblastic T-cell lymphoma

KW - dendritic cell tumors

KW - histiocytic sarcoma

KW - Hodgkin lymphoma

KW - lymphoma classification

KW - Non-Hodgkin lymphoma

KW - peripheral T-cell lymphoma

KW - T-cell lymphoproliferative disorder

KW - World Health Organization (WHO)

UR - http://www.scopus.com/inward/record.url?scp=85014705895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014705895&partnerID=8YFLogxK

U2 - 10.1080/17474086.2017.1281122

DO - 10.1080/17474086.2017.1281122

M3 - Review article

C2 - 28133975

AN - SCOPUS:85014705895

VL - 10

SP - 239

EP - 249

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 3

ER -